Age-standardized mortality-to-incidence ratio for all cancers in the world
Japanese Journal of Clinical Oncology · 08.01.2025 · 55 (1) · 91-92
DOI: 10.1093/jjco/hyae180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 27.12.2024. Verfasst von Kumiko Saika und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of International Health Policy Research, National Cancer Center, Institute for Cancer Control, Tokyo, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 1 Literaturangaben.
Abstract (Originalsprache)
Mortality-to-incidence ratio (MIR) is one of indicators that measure patients’ prognosis. The International Agency for Research on Cancer produces GLOBOCAN estimates of cancer incidence and mortality in 185 countries and showed the age-standardized MIRs were published in ‘Global Cancer Observatory’ website [1]. In this site, the age-adjusted MIRs were calculated by dividing the estimated age-adjusted mortality rate in 2022 by the age-adjusted incidence rate in 2022. Although the numerator and denominator of the MIR are actually different patients, it can be considered as an approximation of the proportion of cancer patients who die from cancer, with a higher value indicating a greater contribution to death from the disease (worse prognosis) and a lower value indicating a smaller contribution to death from the disease (better prognosis). To compare the estimated MIRs for all cancers among six areas (Africa, Europe, Latin America and the Caribbean, Northern America, Oceania and Asia), we plotted the age-adjusted MIRs by countries and combined areas in Fig. 1. Age-standardized mortality-to-incidence ratios for all cancers in 2022. In male, MIR in the world was 0.52, which can be interpreted that 52% of the incidence would die in cancer. All countries in Africa and many countries in Latin America and the Caribbean have MRIs higher than the 0.52 in the world (dots in the upper portion in the graph above the line), indicating a poor prognosis for cancer. In addition, all countries in Northern America (Canada and the USA), many countries in Europe tend to have a better prognosis than the world as a whole, while Asia and Oceania have larger differences by country. In Asia, among 47 countries, Japan has the lower MIR (0.33), and only three countries (Japan, Israel and the Republic of Korea) have MIRs lower than the world. MIRs in female are lower than those in male in all regions, and the size of MIR by region is essentially the same as that in male. In comparison to the MIR in the world, only that in Latin America and the Caribbean was lower than that in the world for male (better prognosis), while for women it was higher than the world (worse prognosis). Note: Data were extracted from the Global Cancer Observatory: Cancer Tomorrow [1]. The figures are prepared by the authors of this article, and the responsibility for their presentation and interpretation lies with the authors of this article. The authoes declare no conflict of interest associated with this article. None declared.
Autor:innen und Institutionen
- Division of International Health Policy Research, National Cancer Center, Institute for Cancer Control, Tokyo, Japan.
Zitieren
APA
Saika, K., & Matsuda, T. (2025). Age-standardized mortality-to-incidence ratio for all cancers in the world. Japanese Journal of Clinical Oncology, 55(1), 91-92. https://doi.org/10.1093/jjco/hyae180
Vancouver
Saika K, Matsuda T. Age-standardized mortality-to-incidence ratio for all cancers in the world. Japanese Journal of Clinical Oncology. 2025;55(1):91-92. doi:10.1093/jjco/hyae180
BibTeX
@article{Saika2025,
author = {Saika, Kumiko and Matsuda, Tomohiro},
title = {Age-standardized mortality-to-incidence ratio for all cancers in the world},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
volume = {55},
number = {1},
pages = {91--92},
doi = {10.1093/jjco/hyae180}
}
EUVIMED